Instead prostate-specific membrane antigen positron emission tomography (PSMA-PET) is emerging as a promising technique to improve tumor lesion detection [8–15], focal therapy guidance [16], and non-invasive PCa characterization [17]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.